Anti-F botulinum toxin neutralizing antibody F13 and related biological material and application thereof

By developing nano-antibody targeting F-type botulinum toxin, the need for treatment of F-type botulinum toxin is solved, providing an efficient and safe neutralization solution, replacing serum products, and meeting human prevention and treatment needs.

CN118955703AActive Publication Date: 2024-11-15ACADEMY OF MILITARY MEDICAL SCIENCES

Patent Information

Application Number
CN202411144356.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-15
Estimated Expiration
2044-08-20

AI Technical Summary

Technical Problem

There is a lack of effective treatments to deal with poisoning caused by Botox type F. There are side effects of existing serum products, and it is urgent to develop efficient and safe anti-Botox type F. Neutralizing antibodies.

Method used

Develop nano-antibody targeting F-type botulinum toxin or antigen-binding fragments containing the nano-antibody, specifically binds to F-type botulinum toxin, and provides efficient neutralization capabilities through specific amino acid sequences and framework regions.

Benefits of technology

It provides an efficient and safe anti-F botulinum toxin neutralizing nano-antibody, which can replace the market-supplied serum products and meets the human needs for the prevention and treatment of F botulinum toxin poisoning, and has the advantages of rapid preparation and multispecific antibodies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention discloses an anti-F botulinum toxin neutralizing antibody F13 as well as a related biological material and application thereof. The invention belongs to the field of immunotherapy, and particularly relates to an anti-F botulinum toxin neutralizing antibody F13 and a related biological material and application thereof. The nano antibody targeting F-type botulinum toxin or the antigen binding fragment containing the nano antibody has three complementary determinants, namely CDR1, CDR2 and CDR3; wherein the amino acid sequence of the CDR1 is the 26 to 33 of SEQ ID No.1, the amino acid sequence of the CDR2 is the 51 to 58 of SEQ ID No.1, and the amino acid sequence of the CDR3 is the 97 to 120 of SEQ ID No.1. The fusion protein F13-hFc obtained by fusing the nano antibody F13 and the Fc segment (hFc) of human immunoglobulin can effectively block poisoning caused by F-type botulinum toxin, and the ED50 (Enhanced Development 50) of the fusion protein F13-hFc for resisting 20 LD50 is 0.0016 nM.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of immunotherapy, and specifically relates to an anti-type F botulinum toxin neutralizing antibody F13 and related biomaterials and applications thereof. Background Art

[0002] Botulinum toxin is the most toxic natural protein known so far. There are seven serotypes, A to G, of which A, B, E, and F are the main types that cause human poisoning. Botulinum toxin poisoning is a potentially fatal disease. Serologically, different types of neurotoxins can prevent the release of acetylcholine at the neuromuscular junction, leading to paralysis. Botulism develops quickly, and vaccination after exposure is useless. Neutralizing antibodies are urgently needed for prevention and treatment. Therefore, countries around the world have doubled their attention to botulism research.

[0003] Antibody therapy is a method for treating botulism. Currently, the only treatment method is antitoxin. Horse serum antitoxin and human immunoglobulin are currently licensed for the treatment of adult and infant botulism, respectively. However, the use of both has side effects such as serum sickness and hypersensitivity reactions including cardiac arrest, which limits their use in treatment and recovery after treatment. At present, highly efficient antitoxins based on monoclonal antibodies are being developed as an effective alternative. Most botulinum antibody drugs are in the molecular discovery stage, and there are no approved drugs. It is urgent to develop antibody drugs to enrich the treatment of poisoning.

[0004] In the 1990s, a unique class of "heavy chain-only" antibodies was discovered in camel serum, which bind to antigens through the variable region, which is called VHH or Nanobody (Nb). Therapeutic nanobodies are in the early stages of development. Their special structure gives them outstanding advantages such as small size, strong stability, and strong antigen binding affinity, making them an ideal substitute for traditional antibodies and widely used in disease diagnosis and treatment, with broad prospects.

[0005] Although botulism caused by botulinum neurotoxin type F is relatively rare, the gene encoding BoNT / F is highly differentiated up to 25%, making it the most diverse of the seven major serotypes. The lack of treatments related to type F botulism highlights the need to treat botulism and urgently requires the development of antibodies with good therapeutic effects. Therefore, this field urgently needs to apply nanoantibody technology to develop efficient and safe anti-type F botulinum toxin neutralizing nanoantibodies to replace serum products supplied on the market to meet human needs. Summary of the invention

[0006] The technical problem to be solved by the present invention is to develop a specific nano-antibody that can effectively neutralize botulinum toxin, provide candidate antibodies for the diagnosis and prevention of botulism, and enrich the means of prevention and treatment of botulism.

[0007] In order to solve the above problems, the present invention provides a nanobody targeting botulinum toxin type F or an antigen-binding fragment containing the nanobody.

[0008] The present invention provides a nanobody targeting botulinum toxin type F or an antigen-binding fragment containing the nanobody, wherein the nanobody has three complementary determining clusters CDR1, CDR2 and CDR3; the amino acid sequence of the CDR1 is shown at positions 26-33 of SEQ ID No.1, the amino acid sequence of the CDR2 is shown at positions 51-58 of SEQ ID No.1, and the amino acid sequence of the CDR3 is shown at positions 97-120 of SEQ ID No.1.

[0009] The above CDRs are sequences defined based on the analysis results of the IMGT system.

[0010] The nanobodies described herein generally include a VHH consisting of four framework regions (FRs) and three complementarity determining regions (CDRs), referred to as FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4, and the antigen-binding fragment comprises at least a portion of the nanobody that is sufficient to confer the fragment the ability to specifically bind to botulinum toxin type F.

[0011] The four framework regions may be FR1, FR2, FR3 and FR4.

[0012] The amino acid sequence of FR1 is positions 1 to 25 of SEQ ID No. 1; The amino acid sequence of FR2 is positions 34-50 of SEQ ID No. 1; The amino acid sequence of FR3 is positions 59-96 of SEQ ID No. 1; The amino acid sequence of FR4 is positions 121-131 of SEQ ID No.1.

[0013] In a specific embodiment, the SEQ ID No. 1 may be as follows: QVQLQESGGGSVQAGGSLRLSCAASGYIYGSNYMGWFRQAPEKEREGIAAIYAGGGSTYYADSVKGRFTISLDNAKATLYLQMNNLKPEDTAMYYCAAVDDPGLVVADTEYILQALAFGSTGQGTQVTVSS.

[0014] In the Nanobody or antigen-binding fragment described above, the Nanobody may be any of the following: A1) a Nanobody with an amino acid sequence as shown in SEQ ID No. 1; A2) A nanobody obtained by connecting a protein tag to the N-terminus and / or C-terminus of the amino acid sequence shown in SEQ ID No. 1.

[0015] The protein tag refers to a polypeptide or protein that is fused and expressed with the target protein to facilitate the expression, detection, tracing and / or purification of the target protein. The protein tag can be a His tag, a Flag tag, an MBP tag, an HA tag, a myc tag, a GST tag and / or a SUMO tag, the Fc segment of immunoglobulin G, etc.

[0016] In the present invention, the protein tag is the Fc segment of human immunoglobulin G (hFc).

[0017] In the above-mentioned nanobody, the nanobody consists of the complementary determining cluster region and the framework region.

[0018] The term "antibody" in the present invention is a heterotetrameric glycoprotein of about 150,000 daltons with identical structural features, which consists of two identical light chains (L) and two identical heavy chains (H). Each light chain is connected to the heavy chain by a covalent disulfide bond, while the number of disulfide bonds between the heavy chains of different immunoglobulin isotypes varies. Each heavy and light chain also has regularly spaced intrachain disulfide bonds. One end of each heavy chain has a variable region (VH), followed by multiple constant regions. Each The light chain has a variable region (VL) at one end and a constant region at the other end; the constant region of the light chain is opposite to the first constant region of the heavy chain, and the variable region of the light chain is opposite to the variable region of the heavy chain. Specific amino acid residues form an interface between the variable regions of the light and heavy chains.

[0019] In the present invention, "variable" means that some parts of the variable region in the antibody are different in sequence, which forms the binding and specificity of various specific antibodies to their specific antigens. However, variability is not evenly distributed throughout the variable region of the antibody. It is concentrated in three segments called complementary determining regions (CDRs) or hypervariable regions in the light chain and heavy chain variable regions. The more conservative part of the variable region is called the framework region (FR). The variable region of the natural heavy chain and light chain each contains four FR regions, which are roughly in a β-folded configuration, connected by three CDRs forming a connecting loop, and in some cases can form a partial β-folded structure. The CDRs in each chain are closely together through the FR region and together with the CDRs of the other chain, form the antigen binding site of the antibody (see Kabat et al., NIH Publ. No. 91-3242, Volume I, 647-669 pages (1991)). The constant region does not directly participate in the binding of the antibody to the antigen, but they exhibit different effector functions, such as participating in the antibody-dependent cytotoxicity of the antibody.

[0020] In the present invention, the terms "single domain antibody (VHH)" and "nanobody" have the same meaning and refer to The variable region of the antibody heavy chain is cloned to construct a single-domain antibody (VHH) consisting of only one heavy chain variable region, which is the smallest antigen-binding fragment with complete functions.

[0021] The above-mentioned antigen-binding fragment may be a complete antibody, a fusion antibody, an antibody-drug conjugate, a Fab fragment, a Fv fragment, a Fab' fragment, a F(ab')2 fragment, a single-chain antibody (ScFv), or a minimum recognition unit (MRU) containing the nanobody.

[0022] The term "Fab fragment" is a heterodimer formed by the heavy chain Fd and the complete light chain bound by disulfide bonds, and contains only one antigen binding site. The heavy chain Fd mentioned above refers to about 1 / 2 of the H chain portion in Fab (containing about 225 amino acid residues, including VH, CH1 and part of the hinge region).

[0023] The term "Fv fragment" refers to the construction of vectors containing VH and VL genes respectively, co-transfection of cells, expression of them separately, and then assembly into functional Fv antibodies; or a stop codon can be set between VH and VL in the vector to express two small molecule protein fragments separately, and then form Fv antibodies (Fv fragments) through non-covalent bonds.

[0024] The term "Fab' fragment" contains one light chain and a portion of one heavy chain including the VH domain and the CH1 domain and the region between the CH1 and CH2 domains, whereby an interchain disulfide bond can be formed between the two heavy chains of the two Fab' fragments to form a F(ab')2 molecule.

[0025] The term "F(ab')2 fragment" contains two light chains and two heavy chains comprising a portion of the constant region between the CH1 and CH2 domains, whereby an interchain disulfide bond is formed between the two heavy chains. Thus, the F(ab')2 fragment consists of two Fab' fragments held together by a disulfide bond between the two heavy chains.

[0026] In some embodiments, the Nanobodies described herein may be truncated at the N- or C-terminus so that they comprise only part of FR1 and / or FR4, or lack one or both of those framework regions, as long as they substantially retain antigen binding and specificity.

[0027] In the present invention, the nanobody is named nanobody F13.

[0028] The present invention also provides a biomaterial related to the nanobody described above, and the biomaterial may be any of the following: B1) a nucleic acid molecule encoding the Nanobody or antigen-binding fragment described above; B2) an expression cassette containing the nucleic acid molecule described in B1); B3) a recombinant vector containing the nucleic acid molecule described in B1); B4) a recombinant vector containing the expression cassette described in B2); B5) a recombinant microorganism containing the nucleic acid molecule described in B1); B6) a recombinant microorganism containing the expression cassette described in B2); B7) a recombinant microorganism containing the recombinant vector described in B3); B8) A recombinant microorganism containing the recombinant vector described in B4).

[0029] In the above biological materials, the nucleic acid molecule may be DNA, such as cDNA, genomic DNA or recombinant DNA; the nucleic acid molecule may also be RNA, such as mRNA or hnRNA.

[0030] In the above-mentioned biological material, the expression cassette described in B2) refers to a DNA capable of expressing the nanobody in a host cell, which may include not only a promoter for initiating transcription of the nanobody encoding gene, but also a terminator for terminating transcription of the nanobody encoding gene. Further, the expression cassette may also include an enhancer sequence.

[0031] In the above biological materials, the vector may be a plasmid, a cosmid, a phage or a virus vector. An existing expression vector may be used to construct a recombinant vector containing the expression cassette.

[0032] In the above-mentioned biological material, the recombinant vector can be a recombinant vector obtained by introducing the nucleic acid molecule described in B1) into the nanobody fusion protein expression vector pTSE-hFc.

[0033] The vector pTSE-hFc is obtained by connecting the gene of the Fc domain of human immunoglobulin to the pCMV vector.

[0034] In the present invention, the recombinant vector may be a recombinant vector pTSE-F13-hFc, and the structure of the pTSE-F13-hFc is described as follows: a DNA fragment having sequence 3 is inserted between the recognition sites of restriction endonucleases Sal I and Nhe I of the pTSE-hFc vector, and the other sequences of the pTSE-hFc vector are kept unchanged to obtain a recombinant vector.

[0035] In the above-mentioned biological material, the host cell comprises the nucleic acid molecule or vector of the nanobody or antigen-binding fragment as described above. The host cell includes, but is not limited to, prokaryotic cells such as Escherichia coli cells, and eukaryotic cells such as yeast cells, animal cells (such as mammalian cells, such as mouse cells, human cells), insect cells and plant cells, etc.

[0036] In the present invention, the cell may be FreeStyle TM HEK293-F cells.

[0037] In the above-mentioned biological material, the nucleic acid molecule described in B1) may be a nucleic acid molecule encoding the nanobody described above, in which the gene encoding the CDR1 is the 76th to 99th nucleotides of SEQ ID No.2, the gene encoding the CDR2 is such as the 151st to 174th nucleotides of SEQ ID No.2, and the gene encoding the CDR3 is such as the 289th to 360th nucleotides of SEQ ID No.2.

[0038] In the above biological material, the nucleic acid molecule in B1) can be any of the following: C1) a DNA molecule whose nucleotide sequence is shown in SEQ ID No. 2; C2) a DNA molecule that hybridizes under stringent conditions with the DNA molecule defined in C1) and encodes said Nanobody; C3) is a DNA molecule that has more than 99%, more than 95%, more than 90%, more than 85% or more homology with any of the DNA sequences defined in C1) to C2) and encodes the Nanobody.

[0039] In a specific embodiment, the SEQ ID No. 2 may be as follows: CAGGTACAGCTGCAGGAGTCTGGGGGAGGCTCGGTGCAGGCTGGAGGGTCTCTGAGACTCTCCTGTGCAGCCTCTGGATACATCTACGGTAGCAACTACATGGGCTGGTTCCGCCAGGCTCCAGAAGGAGCGCGAGGGAATCGCAGCTATTTATGCTGGTGGTGGTAGCACATACTATGCCGACTCCGTGAAGGG CCGATTCACCATCTCCCTAGACAACGCCAAGGCCACATTGTATCTGCAAATGAACAACCTGAAACCTGAGGACACTGCCATGTACTACTGTGCGGCAGTGGACGACCCCGGACTGGTGGTAGCGGATACTGAGTATATCCTCCAGGCCCTTGCTTTTGGTTCCACGGGCCAGGGGACCCAGGTCACCGTCTCCTCA.

[0040] Wherein, the stringent conditions may be as follows: 50°C, hybridization in a mixed solution of 7% sodium dodecyl sulfate (SDS), 0.5M Na3PO4 and 1mM EDTA, and rinsing at 50°C, 2×SSC, 0.1% SDS; it may also be: 50°C, hybridization in a mixed solution of 7% SDS, 0.5M Na3PO4 and 1mM EDTA, and rinsing at 50°C, 1×SSC, 0.1% SDS; it may also be: 50°C, hybridization in a mixed solution of 7% SDS, 0.5M Na3PO4 and 1mM EDTA, and rinsing at 50°C, 0.5×SSC, 0.1% SDS; it may also be: 50°C, hybridization in a mixed solution of 7% SDS, 0.5M Na3PO4 and 1mM EDTA, and rinsing at 50°C, 0.1×SSC, 0.1% SDS; it may also be: 50°C, hybridization in a mixed solution of 7% SDS, 0.5M Na3PO4 and 1mM EDTA, and rinsing at 50°C, 0.1×SSC, 0.1% SDS; it may also be: 50°C, 7% Hybridize in a mixed solution of SDS, 0.5M Na3PO4 and 1mM EDTA, and rinse in 0.1×SSC, 0.1% SDS at 65°C. Alternatively, hybridize in a solution of 6×SSC, 0.5% SDS at 65°C, and then wash the membrane once with 2×SSC, 0.1% SDS and once with 1×SSC, 0.1% SDS.

[0041] A person skilled in the art can easily mutate the nucleotide sequence of the gene encoding the Nanobody F13 described in B1) of the present invention by using known methods, such as directed evolution and point mutation. Those artificially modified nucleotides having 75% or more identity with the nucleotide sequence of F13 described in B1) of the present invention, as long as they encode the Nanobody and have the activity of Nanobody F13, are derived from the nucleotide sequence of the present invention and are equivalent to the sequence of the present invention.

[0042] The present invention also provides a method for preparing the above-mentioned nanoantibody, which may include the following steps: introducing a nucleic acid molecule encoding the nanoantibody described above into a recipient cell to obtain a transgenic cell expressing the nanoantibody, and culturing the transgenic cell to obtain the nanoantibody.

[0043] Furthermore, the nucleic acid molecule encoding the nanobody is the nucleic acid molecule described above.

[0044] In the above preparation method, the nucleotide sequence of the nucleic acid molecule encoding the Nanobody described above can be any of the following: C1) a DNA molecule whose nucleotide sequence is shown as SEQ ID No.1; C2) a DNA molecule that hybridizes under stringent conditions with the DNA molecule defined in C1) and encodes said Nanobody; C3) is a DNA molecule that has more than 99%, more than 95%, more than 90%, more than 85% or more than 80% homology with the DNA sequence defined in C1) or C2) and encodes the Nanobody.

[0045] Furthermore, the recipient cell may be a prokaryotic cell such as an Escherichia coli cell, a eukaryotic cell such as a yeast cell, an animal cell (such as a mammalian cell, such as a mouse cell, a human cell), an insect cell, a plant cell, and the like.

[0046] In a specific embodiment of the present invention, the recipient cell can be E. coli TG1 or FreeStyle TM HEK293-F cells.

[0047] The present invention also provides a nanobody fusion protein, which is a fusion of the nanobody or antigen-binding fragment described above with another molecule, wherein the other molecule may include an immunoglobulin Fc domain, a fluorescent protein, or a VHH with different specificities.

[0048] In a specific embodiment of the present invention, the other molecule is the Fc domain of a human immunoglobulin.

[0049] In a specific embodiment of the present invention, the amino acid sequence of the Fc domain of the human immunoglobulin described above is positions 367-594 of SEQ ID No.4.

[0050] In a specific embodiment of the present invention, the Nanobody fusion protein described above may be any of the following: M1) a fusion protein with an amino acid sequence as shown in SEQ ID No.4; M2) A fusion protein obtained by replacing and / or deleting and / or adding amino acid residues of the protein of M1) and having an identity of more than 75% with the protein of M1); M3) A protein obtained by connecting a protein tag to the N-terminus and / or C-terminus of the amino acid sequence shown in SEQ ID No. 4.

[0051] In the above-mentioned nanobody fusion protein, the nucleic acid molecule encoding the fusion protein may be any of the following: D1) a DNA molecule with a nucleotide sequence as shown in SEQ ID No. 3; D2) a DNA molecule that hybridizes with the DNA molecule defined in D1) under stringent conditions and encodes the fusion protein; D3) A DNA molecule that has 99% or more, 95% or more, 90% or more, 85% or more, or 80% or more homology with the DNA sequence defined in D1) or D2) and encodes the fusion protein.

[0052] In a specific embodiment, the nanobody fusion protein is F13-hFc.

[0053] The present invention also provides an ELISA detection kit targeting botulinum toxin type F, wherein the kit comprises the nanoantibody, the biomaterial or the fusion protein described above.

[0054] The present invention also provides any of the following applications: E1) Use of the aforementioned Nanobody or antigen-binding fragment in the preparation of a product for detecting botulinum toxin type F; E2) Use of the aforementioned biological material in the preparation of a product for detecting botulinum toxin type F; E3) Use of the preparation method described above in the preparation of a product for detecting botulinum toxin type F; E4) Use of the above-mentioned kit in the preparation of a product for detecting botulinum toxin type F; E5) Use of the aforementioned nanoantibody in the preparation of a product bound to botulinum toxin type F; E6) Use of any of the above-mentioned biological materials in the preparation of a product combined with botulinum toxin type F; E7) Use of the above-mentioned preparation method in the preparation of a product combined with botulinum toxin type F; E8) Use of the kit described above in the preparation of a product combined with botulinum toxin type F; E9) Use of the aforementioned nanoantibodies or antigen-binding fragments in the preparation of a botulinum toxin type F detection reagent; E10) Use of the nanoantibodies or antigen-binding fragments described above in the preparation of botulinum toxin type F diagnostic reagents; E11) Use of the nanoantibodies or antigen-binding fragments described above in the preparation of drugs for the prevention and / or treatment of botulinum toxin type F.

[0055] The above-mentioned product may be a medicine.

[0056] The present invention includes not only complete antibodies, but also fragments of the nanobodies or fusion proteins formed by antibodies and other sequences with immunological activity. Therefore, the present invention also includes polypeptides such as fragments, derivatives and analogs of the nanobodies that retain the same biological functions or activities as the antibodies of the present invention. The polypeptides may be as follows: D1) a single-chain antibody containing the nanobodies described above; D2) a Fab containing the nanobodies described above; D3) a complete antibody containing the nanobodies described above; D4) a fusion antibody containing the nanobodies described above; D5) an antibody-drug conjugate containing the nanobodies described above.

[0057] D4) The fusion antibody of the nanobody may be a nanobody fusion protein whose amino acid sequence is shown in SEQ ID No.4.

[0058] As known to those skilled in the art, the conjugates and fusion antibody expression products include: drugs, toxins, cytokines (cytokines), radionuclides, enzymes and other diagnostic or therapeutic molecules combined with the antibodies of the present invention or their fragments to form conjugates. The present invention also includes cell surface markers or antigens combined with the nano antibodies or their fragments.

[0059] The present invention includes any protein or protein conjugate and fusion expression product (i.e., immunoconjugate and fusion expression product) having a heavy chain containing a variable region, as long as the variable region is identical to or at least 90% homologous to the heavy chain variable region of the antibody of the present invention, preferably at least 95% homologous.

[0060] The present invention prepares a phage nanoantibody display library by immunizing camels with antigens and screens to obtain the nanoantibody F13-hFc capable of neutralizing type F botulinum toxin. The nanoantibody has the advantages of rapid preparation, simple structure and easy transformation into multi-specific antibodies. It is expected to be developed into a highly efficient and safe anti-type F botulinum toxin neutralizing nanoantibody to replace the serum products supplied on the market to meet human needs. BRIEF DESCRIPTION OF THE DRAWINGS

[0061] Figure 1 This is the binding status of some phage clones with target antigen or control antigen after the third round of screening by Phage-ELISA. The odd-numbered columns are target antigens, and the even-numbered columns are control antigens.

[0062] Figure 2 The SDS-PAGE electrophoresis is used to detect the purified anti-F-type botulinum toxin nanobody-hFc fusion protein F13-hFc. M is a marker band, lane 1 is the non-reducing SDS-PAGE detection result of F13-hFc, and lane 2 is the reducing SDS-PAGE detection result of F13-hFc.

[0063] Figure 3 This is the detection of the binding activity of anti-botulinum toxin type F nanobody-hFc fusion protein F13-hFc.

[0064] Figure 4 It is a specific detection of anti-F type botulinum toxin nanobody-hFc fusion protein F13-hFc. AHc, BHc, EHc, and FHc are the Hc antigens of the four serotypes of botulinum toxin A, B, E, and F respectively; THc is the Hc antigen of tetanus toxin; and FL-HN is the L-HN antigen of F type botulinum toxin.

[0065] Figure 5The neutralization activity of the anti-type F botulinum toxin nanobody-hFc fusion protein F13-hFc was evaluated. BoNT / F is type F botulinum toxin, Ab is the Fc fusion protein F13-hFc of the anti-type F botulinum toxin nanobody F13 and human immunoglobulin, and BAT-F is a standard solution of horse-derived type F botulinum antitoxin. DETAILED DESCRIPTION

[0066] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.

[0067] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.

[0068] Unless otherwise specified, the quantitative tests in the following examples were performed three times and the results were averaged.

[0069] The botulinum toxin type F (BoNT / F) and the equine botulinum antitoxin standard solution (BAT-F) in the following examples were purchased from the China Food and Drug Inspection Institutes.

[0070] The NEN-SCFV in the following examples is obtained by connecting the genes of the phage surface protein pill and the arabinose operon to the pET vector. NEN-SCFV has been recorded in: Chen L, Lu J, Yue J, Wang R, Du P, YuY, Guo J, Wang X, Jiang Y, Cheng K, Yang Zand Zheng T (2023) A humanized antihuman adenovirus 55 monoclonal antibody with good neutralizationability. Front. Immunol. 14:1132822. doi: 10.3389 / fimmu.2023.1132822. The public can obtain the biological material from the applicant, and the biological material is only used for repeating the experiment of the present invention and cannot be used for other purposes.

[0071] The pTSE-hFc in the following embodiment is obtained by connecting the gene of the Fc domain of human immunoglobulin to the pCMV vector. pTSE-hFc has been recorded in: Xie Qing, Li Zhiying, Zhang Wei, etc. Screening and identification of antibodies against the protective antigen V of plague bacteria [J]. Chinese Journal of Pathogenic Biology, 2022, 17(03): 266-271. The public can obtain the biological material from the applicant. The biological material is only used for repeating the experiments of the present invention and cannot be used for other purposes.

[0072] The Hc antigen of tetanus toxin in the following examples was prepared by this laboratory, and the preparation method has been recorded in: LiuXY, Wei DK, Li ZY, Lu JS, Xie XM, Yu YZ, Pang XB. Immunogenicity andimmunoprotection of the functional TL-HN fragment derived from tetanus toxin.Vaccine. 2023: S0264-410X(23)01102-7. doi: 10.1016 / j.vaccine.2023.09.032. The public can obtain the biological material from the applicant. The biological material is only used for repeating the experiments of the present invention and cannot be used for other purposes.

[0073] The Hc antigens AHc, BHc, EHc, and FHc of the four serotypes of botulinum toxin A, B, E, and F in the following examples were prepared by this laboratory, and the preparation method has been recorded in: Shi DY, Liu FJ, Li ZY, Mao YY, Lu JS, Wang R, PangXB, Yu YZ, Yang ZX. Development and evaluation of a tetravalent botulinumvaccine. Hum Vaccin Immunother. 2022;18(5):2048621. doi: 10.1080 / 21645515.2022.2048621. The public can obtain the biological material from the applicant. The biological material is only used for repeating the experiments of the present invention and cannot be used for other purposes.

[0074] The L-HN antigen of botulinum toxin type F in the following examples was prepared by our laboratory, and the preparation method has been described in: LiZY, Li BL, Lu JS, Liu XY, Tan X, Wang R, Du P, Yu, S, Xu Q, Pang XB, Yu YZ, Yang ZX. Biological and Immunological Characterization of a Functional L-HNDerivative of Botulinum Neurotoxin Serotype F. Toxins 2023; 15(3), 200. doi:10.3390 / toxins15030200. The public can obtain the biological material from the applicant. The biological material is only used for repeating the experiments of the present invention and cannot be used for other purposes.

[0075] The irrelevant control antibody (T23) in the following examples was prepared by this laboratory. The preparation method is as follows: immunizing camels with tetanus TL-HN protein, isolating camel peripheral blood lymphocytes, amplifying VHH gene fragments by nested PCR, constructing a specific nano antibody phage library and screening to obtain nano antibody molecules that specifically bind to TL-HN protein, and one of the antibodies is named T23. The public can obtain the biological material from the applicant, and the biological material is only used for repeating the experiment of the present invention and cannot be used for other purposes.

[0076] The following examples used GraphPad Prism 8 software to process the data, and the experimental results were expressed as mean ± standard deviation. One-way ANOVA test was used, and P < 0.05 (*) indicated a significant difference, P < 0.01 (**) indicated a very significant difference, and P < 0.001 (***) indicated an extremely significant difference.

[0077] Example 1. Construction of anti-botulinum toxin type F nanobody library 1. Camel Immunity The BoNT / F-Hc antigen was mixed with an equal volume of Freund's complete adjuvant (Sigma, F5881), shaken and emulsified, and then injected into healthy adult Bactrian camels by subcutaneous multi-point injection after sufficient emulsification. Thereafter, booster immunizations were performed every two weeks. Except for the first immunization using Freund's complete adjuvant, all other immunizations used Freund's incomplete adjuvant (Sigma, F5506).

[0078] 2. Isolation of peripheral blood lymphocytes from camels 150 mL of peripheral blood from camels that had been immunized five times was collected into anticoagulation tubes to separate peripheral blood lymphocytes (PBMC). The whole blood sample was gently diluted and mixed with lymphocyte separation solution (STEMCELL, 07851) to form a mixture with a clear interface between the two to separate peripheral blood lymphocytes from camel blood. After the mixture of whole blood and lymphocyte separation solution was centrifuged, the liquid in the centrifuge tube was divided into four layers from top to bottom: plasma layer, PBMC layer, lymphocyte separation solution layer and red blood cell layer.

[0079] 3. Nested PCR amplification of VHH gene fragments Total RNA from PBMCs was extracted using the OMEGA EZNA Total RNA kit I (OMEGA, R6834), and then reverse transcribed to obtain cDNA using the Invitrogen Superscript Ⅲ First-strand synthesis system for RT-PCR kit (Invitrogen, 18080-051).

[0080] The first round of PCR: using the synthesized cDNA as a template, the antibody CH2 region sequence was PCR amplified with the designed IgG-specific upstream primer CALL001 and downstream primer CALLOO2; using the recovered first-round PCR product as a template, the second round of PCR amplification was performed with the designed primers VHH-F and VHH-R to amplify the VHH fragment.

[0081] Table 1. Primer sequences used in two rounds of PCR

[0082] 4. Electroporation products The vector NEN-SCFV and the VHH gene amplified in step 3 were digested with restriction endonucleases NcoⅠ and NotⅠ, and the ligation product was constructed by ligation with T4 ligase.

[0083] The ligation product was transformed into E. coli An anti-botulinum toxin type F specific phage antibody library was constructed in TG1 competent cells (Beijing Huayueyang Biotechnology Co., Ltd., WG1220), and the phage antibody library was diluted in multiple ratios to determine its capacity and transformation efficiency.

[0084] After identification, the library capacity of this antibody library reached 4×10 8 To detect the accuracy of the library, 48 clones were randomly selected for colony PCR, and sequence comparison results showed that the VHH fragment insertion rate reached 100% and the sequences were different.

[0085] Example 2: Screening of anti-botulinum toxin type F specific nanoantibody phage library Prepare the following culture media and solutions: 2YT-GA medium (1 L): 16 g Typtone, 10 g Yeast Extract, 5 g NaCl, 100 μg / mL ampicillin, 20% glucose, and the rest water.

[0086] 2YT-KAA medium (1 L): 16 g Typtone, 10 g Yeast Extract, 5 g NaCl, 100 μg / mL kanamycin, 20% glucose, final concentration 1 mM arabinose, and the rest water.

[0087] PBST (1 L): contains 8.0 g NaCl, 0.2 g KCl, 1.42 g Na2HPO4, 0.27 g KH2PO4, 0.1% Tween-20, and the rest is water.

[0088] Using BoNT / F-Hc as the antigen, the constructed nanoantibody phage library was used for solid phase screening to obtain anti-type F botulinum toxin-specific nanoantibodies.

[0089] The constructed anti-F type botulinum toxin specific nanoantibody phage library was transferred to 2YT-GA medium (1L) and cultured to the logarithmic growth phase. M13KO7 helper phage was added at a ratio of MOI≈10. After standing at room temperature for infection for 30 min, it was cultured at 37 ℃ and low speed 150 rpm for 30 min. The deep-well plate was placed at a speed of 4000 rpm, centrifuged at room temperature for 15 min, and the supernatant was discarded. 2YT-KAA medium (1 L) was used for overnight display. The culture display supernatant was collected the next day, and the phage was concentrated with 20% PEG / NaCl solution (1 L solution contains 200 g PEG6000 and 146.25 g NaCl) to obtain high-titer antibody library display products for subsequent screening. The nanoantibody phage library was used to screen specific nanoantibodies on a solid phase. The BoNT / F-Hc protein was coated with 0.05 M NaHCO3 coating solution (pH=9.6) to the immunotube and incubated overnight at 4°C. The next day, the immunotube was washed twice with PBS, 3 min / time, and blocked with blocking solution (2% bovine serum albumin) at room temperature for 2 h. The nanoantibody phage library solution was added and incubated at room temperature for 2 h. The tube was then shaken at a low speed of 200 rpm for 20 min. The tube was washed with PBST (1 L) and then PBS for 5 times. After washing, 1 mL of elution solution (0.1 M Glycine-HCl, pH 2.2) was added and eluted at 400 rpm for 20 min. The elution solution in the target antigen immunotube was taken out and neutralized with 20-60 µL of neutralization solution (1 M Tris-HCl, pH 8.0). Escherichia coli TG1 in the logarithmic growth phase was infected and allowed to stand at room temperature for 30 min. The tube was shaken at 37°C and 150 rpm. The cells were cultured at rpm for 30 min, and the phages were produced and purified for the next round of screening. The same screening process was repeated for 3 rounds, and the enrichment results are shown in Table 2.

[0090] Table 2. Analysis of the enrichment degree of anti-type F botulinum toxin phage nanoantibody library screening

[0091] After the above three rounds of screening, single clones with obvious intervals and regular shapes were selected from the plates with good phage growth, and inoculated into 96-well deep-well plates containing 250 μL of 2YT-GA medium in each well, of which 2 clones not inoculated or inoculated with other antibodies were left as negative control wells; after the bacterial solution was cultured at 37°C to the logarithmic growth phase, M13KO7 helper phage (NEW ENGLAND BioLabs, N0315S) was added at a ratio of MOI≈10, that is, 100 μL was added to each well of the deep-well plate where a single phage clone was cultured, and the infection was allowed to stand at room temperature for 30 min, and then cultured at 37°C and a low speed of 150 rpm for 30 min; the deep-well plate was placed at a speed of 2000 rpm, centrifuged at room temperature for 10 min, and the supernatant was discarded, and expression was induced using arabinose containing a final concentration of 1 mM, and cultured overnight at 28°C and a speed of 220 rpm to obtain phage particles displaying nanoantibodies.

[0092] Example 3: Phage-ELISA to Identify Botulinum Toxin Type F-Specific Nanobodies The ELISA plate was coated with BoNT / F-Hc protein as antigen, and the antigen concentration was diluted to 2 ng / μL with 0.05 M NaHCO3 coating solution, with a dosage of about 200 ng / well. The adjacent column of the antigen column was coated with 2% BSA antigen in parallel as a negative control, and the coating was carried out overnight at 4°C. The next day, the ELISA plate was taken out, washed 6 times with PBST on a plate washer, and then blocked with blocking solution (30 g skim milk powder added to 1 L PBS) at 200 μL / well, and blocked at 37°C for 2 h. The monoclonal bacterial solution induced overnight was centrifuged at 4°C and 3000 rpm for 10 min, and 125 μL of supernatant from each bacterial solution was taken into a 96-well deep-well plate with 125 μL of blocking solution, and pre-bound for 30 min. The blocked induced expression supernatant was added to the corresponding ELISA plate coated with the target antigen and control antigen at 100 μL / well, and incubated at 37°C for 1.5 h.

[0093] After washing with PBST for 6 times on a plate washer, HRP-labeled anti-M13 mouse monoclonal antibody (Sino Bioligical, 1973-MM05T-H) was diluted 4000 times with blocking solution and added to the ELISA plate at 100 µL / well and incubated at 37 °C for 45 min; after washing with PBST for 6 times on a plate washer, color development solution (10 mL of color development solution containing 1 mL 10×OPD, 9 mL of a mixed solution of 0.2 M Na2HPO4 and 0.1 M citric acid, and 10 µL of 30% hydrogen peroxide) was prepared and added to the ELISA plate at 100 µL / well and color was developed for 15-20 minutes in the dark; 2 M H2SO4 stop solution was added at 50 µL / well to terminate the reaction; the plate was read at a dual wavelength of 492 / 630 nm using an ELISA reader, and the monoclonal clones with a light absorbance ratio of the antigen group to the negative control group greater than 5 were determined as positive clones. Some Phage-ELISA experimental results are shown in Figure 1 The odd-numbered columns are target antigens, and the even-numbered columns are control antigens. The bacterial solution corresponding to the positive clones was sent to a biotechnology service company for sequence determination to obtain the DNA sequence of the inserted fragment, and finally a phage clone F13 that can specifically bind to BoNT / B-Hc was obtained.

[0094] The amino acid sequence of Nanobody F13 is as shown in SEQ ID No. 1: it includes a framework region (FR: FR1, FR2, FR3, FR4) and a complementary determining region (CDR: CDR1, CDR2, CDR3), wherein the amino acid sequence of the complementary determining region CDR1 is shown in positions 26-33 of SEQ ID No. 1, the amino acid sequence of CDR2 is shown in positions 51-58 of SEQ ID No. 1, and the amino acid sequence of CDR3 is shown in positions 97-120 of SEQ ID No. 1; the four parts of the framework region are respectively recorded as positions 1-25 of SEQ ID No. 1, positions 34-50 of SEQ ID No. 1, positions 59-96 of SEQ ID No. 1, and positions 121-131 of SEQ ID No. 1.

[0095] Wherein SEQ ID No.1: QVQLQESGGGSVQAGGSLRLSCAASGYIYGSNYMGWFRQAPEKEREGIAAIYAGGGSTYYADSVKGRFTISLDNAKATLYLQMNNLKPEDTAMYYCAAVDDPGLVVADTEYILQALAFGSTGQGTQVTVSS.

[0096] The nucleotide sequence of the gene encoding the above-mentioned anti-type F botulinum toxin nanobody F13 is shown in SEQ ID No.2.

[0097] SEQ ID No.2: CAGGTACAGCTGCAGGAGTCTGGGGGAGGCTCGGTGCAGGCTGGAGGGTCTCTGAGACTCTCCTGTGCAGCCTCTGGATACATCTACGGTAGCAACTACATGGGCTGGTTCCGCCAGGCTCCAGAAGGAGCGCGAGGGAATCGCAGCTATTTATGCTGGTGGTGGTAGCACATACTATGCCGACTCCGTGAAGGG CCGATTCACCATCTCCCTAGACAACGCCAAGGCCACATTGTATCTGCAAATGAACAACCTGAAACCTGAGGACACTGCCATGTACTACTGTGCGGCAGTGGACGACCCCGGACTGGTGGTAGCGGATACTGAGTATATCCTCCAGGCCCTTGCTTTTGGTTCCACGGGCCAGGGGACCCAGGTCACCGTCTCCTCA.

[0098] Example 4. Preparation of anti-botulinum toxin type F nanobody 1. Construction of the eukaryotic expression plasmid pTSE-F13-hFc of anti-type F botulinum toxin nanoantibody hFc fusion protein According to the gene sequence of anti-type F botulinum toxin nanobody F13 (SEQ ID No. 2), its carboxyl terminus was connected to the hFc segment of human immunoglobulin to form an anti-type F botulinum toxin nanobody hFc fusion protein. The encoding nucleotide sequence of this fusion protein is shown in SEQ ID No. 3, and the amino acid sequence of the fusion protein is shown in SEQ ID No. 4.

[0099] SEQ ID No.3:

[0100] SEQ ID No.4: QVQLQESGGGSVQAGGSLRLSCAASGYIYGSNYMGWFRQAPEKEREGIAAIYAGGGSTYYADSVKGRFTISLDNAKATLYLQMNNLKPEDTAMYYCAAVDDPGLVVADTEYILQALAFGSTGQGTQVTVSSASDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVLHEALHSHYTQKSLSLSPGK.

[0101] The obtained F13 gene sequence was cloned into the pTSE-hFc expression vector through basic PCR amplification, restriction digestion, ligation and other techniques, and a single clone was selected for sequencing verification. After the amplified VHH gene fragment was successfully inserted into the corresponding vector, a eukaryotic expression plasmid was constructed, and the obtained recombinant plasmid was named pTSE-F13-hFc.

[0102] The structure of the recombinant vector pTSE-F13-hFc is described as follows: a DNA fragment having a sequence of SEQ ID No. 2 is inserted between the recognition sites of restriction endonucleases Sal I and Nhe I of the pTSE-hFc vector, and the other sequences of the pTSE-hFc vector are kept unchanged to obtain a recombinant vector. The recombinant vector pTSE-F13-hFc can express the nanobody fusion protein F13-hFc.

[0103] 2. Expression and purification of anti-botulinum toxin nanoantibody fusion protein F13-hFc The constructed pTSE-F13-hFc expression plasmid was transfected into FreeStyle TM In HEK293-F cells (Invitrogen, R79007), cell activity was monitored daily starting after 72 hours. When the cell activity dropped from 95-100% to 80-85%, the cell supernatant was collected for purification to obtain the nanobody fusion protein F13-hFc.

[0104] The purified antibody was analyzed by SDS-PAGE electrophoresis. Figure 2 As shown: The molecular weight of antibody F13-hFc is in line with expectations, and the band size of nanobody fusion protein F13-hFc under reducing conditions is approximately 40 kDa ( Figure 2 Lane 2), the band size under non-reducing conditions is approximately 80 kDa ( Figure 2 middle lane 1).

[0105] Example 5. Evaluation of the properties of the nanobody fusion protein F13-hFc 1. The binding activity between the nanobody fusion protein F13-hFc and BoNT / F-Hc protein was detected by ELISA experiment. The experimental method is as follows: The BoNT / F-Hc protein concentration was diluted to 2 μg / mL with carbonate coating buffer (pH 9.6), and 100 μL / well was added to a 96-well ELISA plate for coating overnight at 4°C. The coating solution was discarded, and the plate was washed 6 times with PBST (1 L PBS solution contains 8.0 g NaCl, 0.2 g KCl, 1.42 g Na2HPO4, 0.27 g KH2PO4, and 0.1% Tween-20) on a plate washer. The residual liquid in the plate was patted dry, and blocking solution (3% skim milk powder) was added at 200 μL / well, and blocked at 37°C for 2 h. The antibody for binding activity detection was diluted 2-fold with blocking solution, with an initial dilution of 100 μg / mL. The blocking solution in the plate was discarded, and the residual liquid was patted dry after washing 6 times with PBST. The F13-hFc to be tested was added to the plate at 100 μL / well, and incubated at 37°C for 1.5 h; dilute HRP-labeled goat anti-human IgG with blocking solution at a ratio of 1:4000, discard the primary antibody, wash 6 times with PBST, add 100 µL / well to the plate, and incubate at 37°C for 45 min; discard the secondary antibody, wash 6 times with PBST, add 100 µL / well peroxidase substrate colorimetric solution, color for 15-20 min in the dark, observe the color development effect, and add 50 µL / well 2 M sulfuric acid to terminate the reaction after color development is complete; use a microplate reader at 492 nm / 630 nm to measure the optical density. By calculating the concentration required for the antibody to bind 50% of the antigen protein (EC 50 ), and evaluate the binding ability between them.

[0106] The results are as follows Figure 3 As shown, the binding half effective concentration (EC 50 ) is 0.293 nM.

[0107] 2. The specificity of the nanobody was identified by ELISA experiment. The experimental method is as follows: BoNT / A-Hc, BoNT / B-Hc, BoNT / E-Hc, BoNT / F-Hc, BoNT / FL-HN, and TeNT-Hc were diluted to 2 µg / mL with carbonate coating buffer, and 100 µL / well was added to a 96-well ELISA plate and coated overnight at 4°C. The next day, the coating solution was discarded, and the coated 96-well plate was washed 6 times with PBST (0.1% Tween-20) on a plate washer. After that, the residual liquid in the wells was patted dry, and blocking solution (3% skim milk powder) was added at 200 µL / well, and blocked at 37°C for 2 h. The primary antibody solution of F13-hFc protein was prepared, and the antibody concentration was diluted to 6 µg / mL. The blocking solution was discarded, and the plate was washed 6 times with PBST and patted dry. F13-hFc was added at 100 µL / well, and incubated at 37°C for 1.5 h; dilute HRP-labeled goat anti-human IgG with blocking solution at a ratio of 1:4000, discard the primary antibody, wash 6 times with PBST, add 100 µL / well to the plate, and incubate at 37°C for 45 min; discard the secondary antibody, wash 6 times with PBST, add 100 µL / well peroxidase substrate colorimetric solution, develop for 15-20 min in the dark, observe the color development effect, and add 50 µL / well 2 M sulfuric acid to terminate the reaction after complete color development; use a microplate reader at 492 nm / 630 nm dual wavelengths to measure the optical density value, and the data results are analyzed using GraphPad Prism 8 software.

[0108] The results are as follows Figure 4 As shown, the nanobody fusion protein F13-hFc specifically binds to the BoNT / F-Hc antigen, but does not bind to other antigens, or the binding activity is very weak.

[0109] Example 6. Evaluation of the neutralizing activity of anti-botulinum toxin nanobodies 1. Sample preparation Diluent: KH2PO4 0.7 g, Na2HPO4•12H2O 2.4 g, NaCl 6.8 g, gelatin 2 g, add water to 1 L, autoclave; Botulinum toxin solution: Dilute botulinum toxin type F (purchased from China Food and Drug Inspection Institute) to 100 LD with diluent. 50 / mL; F13-hFc solution: a solution obtained by dissolving the fusion protein F13-hFc prepared in Example 4 in a diluent.

[0110] Horse botulinum antitoxin standard solution (BAT-F): A solution obtained by dissolving horse anti-botulinum toxin serum (purchased from China Food and Drug Inspection Institute) in diluent.

[0111] 2. Specific experimental groups The neutralizing activity of the antibody was determined by mixing the antibody with a lethal dose of botulinum toxin type F in vitro and then injecting it into KM mice (Kunming, purchased from Beijing Sibeifu Biotechnology Co., Ltd.). There were 4 KM mice in each group, weighing 18-20 g, and the health status and survival of the mice were monitored for 7 days. The groups were as follows: (1) BoNT / F solution 20×LD 50 Group: Each KM mouse was intraperitoneally injected with 200 μL of 100×LD 50 / mL of botulinum toxin solution, so that the toxin dose contained in each injection solution is 20×LD 50 / Only.

[0112] (2) BoNT / F 20×LD 50 +F13-hFc-0.016 μg group: The above botulinum toxin solution was mixed with the F13-hFc solution, and the volume of each group was supplemented to 2.5 mL with diluent. After mixing evenly, the solution was incubated at 37 °C for 30 min to obtain BoNT / F + F13-hFc solution, which was intraperitoneally injected into KM mice, with 500 μL injected per mouse, so that the dose of BoNT / F was 20×LD 50 / mouse, so that the dose of F13-hFc in each injection solution is 0.016 μg / mouse.

[0113] (3) BoNT / F 20×LD 50 +F13-hFc-0.008 μg group: The difference between this group and BoNT / F +F13-hFc-0.016 μg group is that the dose of F13-hFc is 0.008 μg / mouse. The rest of the operation is the same as BoNT / F 20×LD 50 +F13-hFc-0.016μg group.

[0114] (4) BoNT / F 20×LD 50 +F13-hFc-0.004 μg group: The difference between this group and BoNT / F +F13-hFc-0.016 μg group is that the dose of F13-hFc is 0.004 μg / mouse. The rest of the operation is the same as BoNT / F 20×LD 50 +F13-hFc-0.016μg group.

[0115] (5) BoNT / F 20×LD 50+F13-hFc-0.002 μg group: The difference between this group and BoNT / F +F13-hFc-0.016 μg group is that the dose of F13-hFc is 0.002 μg / mouse. The rest of the operation is the same as BoNT / F 20×LD 50 +F13-hFc-0.016μg group.

[0116] (6) BoNT / F 20×LD 50 +F13-hFc-0.001 μg group: The difference between this group and BoNT / F +F13-hFc-0.016 μg group is that the dose of F13-hFc is 0.001 μg / mouse. The rest of the operation is the same as BoNT / F 20×LD 50 +F13-hFc-0.016μg group.

[0117] (7) BoNT / F 20×LD 50 +BAT-F-0.2 IU group: The botulinum toxin solution was mixed with the standard solution of horse botulinum antitoxin, and the volume of each group was supplemented to 2.5 mL with diluent. After mixing evenly, the solution was incubated at 37 °C for 30 min to obtain BoNT / F +BAT-F solution, which was intraperitoneally injected into KM mice, 500 μL per mouse, so that the dose of botulinum toxin was 20×LD 50 / mouse, and the dose of horse botulinum antitoxin BAT-F was 0.2 IU / mouse.

[0118] The results are as follows Figure 5 As shown, 0.008 μg of F13-hFc can completely neutralize 20×LD 50 Lethal dose of BoNT / F.

[0119] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.

Claims

1. A nanobody targeting botulinum toxin type F or an antigen-binding fragment containing the nanobody, characterized in that: The nanobody has three complementary determining clusters CDR1, CDR2 and CDR3; the amino acid sequence of the CDR1 is shown at positions 26-33 of SEQ ID No.1, the amino acid sequence of the CDR2 is shown at positions 51-58 of SEQ ID No.1, and the amino acid sequence of the CDR3 is shown at positions 97-120 of SEQ ID No.

1.

2. The nanobody or antigen-binding fragment according to claim 1, characterized in that The Nanobody is the following A1) or A2): A1) a Nanobody with an amino acid sequence as shown in SEQ ID No. 1; A2) A nanobody obtained by connecting a protein tag to the N-terminus and / or C-terminus of the amino acid sequence shown in SEQ ID No.

1.

3. A biomaterial associated with the Nanobody of claim 1 or 2, wherein the biomaterial is any of the following: B1) a nucleic acid molecule encoding the Nanobody or antigen-binding fragment of claim 1 or 2; B2) an expression cassette containing the nucleic acid molecule described in B1); B3) a recombinant vector containing the nucleic acid molecule described in B1); B4) a recombinant vector containing the expression cassette described in B2); B5) a recombinant microorganism containing the nucleic acid molecule described in B1); B6) a recombinant microorganism containing the expression cassette described in B2); B7) a recombinant microorganism containing the recombinant vector described in B3); B8) A recombinant microorganism containing the recombinant vector described in B4).

4. The biomaterial according to claim 3, characterized in that B1) The nucleic acid molecule is a nucleic acid molecule encoding the Nanobody according to claim 1 or 2, in which the CDR1 encoding gene is nucleotides 76-99 of SEQ ID No. 2, the CDR2 encoding gene is such as nucleotides 151-174 of SEQ ID No. 2, and the CDR3 encoding gene is such as nucleotides 289-366 of SEQ ID No.

2.

5. A method for preparing the Nanobody according to claim 1 or 2, comprising the following steps: The nucleic acid molecule encoding the nanobody according to claim 1 or 2 is introduced into a recipient cell to obtain a transgenic cell expressing the nanobody, and the transgenic cell is cultured to obtain the nanobody.

6. The biomaterial according to claim 3 or 4 or the preparation method according to claim 5, characterized in that: B1) The nucleic acid molecule is any of the following: C1) a DNA molecule whose nucleotide sequence is shown in SEQ ID No. 2; C2) a DNA molecule that hybridizes under stringent conditions with the DNA molecule defined in C1) and encodes said Nanobody; C3) is a DNA molecule that has more than 99%, more than 95%, more than 90%, more than 85% or more homology with the DNA sequence defined in C1) or C2) and encodes the Nanobody.

7. A nanobody fusion protein, characterized in that: The nanobody fusion protein is a fusion of the nanobody or antigen-binding fragment of claim 1 or 2 with another molecule, wherein the other molecule includes an Fc domain of an immunoglobulin, a fluorescent protein, or a VHH with different specificity.

8. The nanobody fusion protein according to claim 7, characterized in that The fusion protein is any of the following: M1) a fusion protein with an amino acid sequence as shown in SEQ ID No.4; M2) A protein obtained by connecting a protein tag to the N-terminus and / or C-terminus of the amino acid sequence shown in SEQ ID No.

4.

9. An ELISA detection kit targeting botulinum toxin type F, characterized in that: The kit comprises the nanobody according to claim 1 or 2, the biological material according to any one of claims 3-5, or the fusion protein according to claim 7 or 8.

10. Any of the following applications: E1) Use of the Nanobody or antigen-binding fragment of claim 1 or 2 in the preparation of a product for detecting botulinum toxin type F; E2) Use of the biological material according to any one of claims 3 to 5 in the preparation of a product for detecting botulinum toxin type F; E3) Use of the preparation method according to claim 6 or 7 in the preparation of a product for detecting botulinum toxin type F; E4) Use of the kit according to claim 9 in the preparation of a product for detecting botulinum toxin type F; E5) Use of the Nanobody of claim 1 or 2 in the preparation of a product bound to botulinum toxin type F; E6) Use of the biomaterial according to any one of claims 3 to 5 in the preparation of a product combined with botulinum toxin type F; E7) Use of the preparation method according to claim 6 or 7 in the preparation of a product combined with botulinum toxin type F; E8) Use of the kit according to claim 9 in the preparation of a product combined with botulinum toxin type F; E9) Use of the nanobody or antigen-binding fragment of claim 1 or 2 in the preparation of a botulinum toxin type F detection reagent; E10) Use of the nanobody or antigen-binding fragment of claim 1 or 2 in the preparation of a botulinum toxin type F diagnostic reagent; E11) Use of the nanobody or antigen-binding fragment of claim 1 or 2 in the preparation of a medicament for preventing and / or treating botulinum toxin type F infection.

Citation Information

Patent Citations

  • Nano antibody for resisting botulinum toxin and application of nano antibody

    CN117736318A

  • Neutralizing antibody against botulinum toxin type B as well as related biological material and application thereof

    CN118063603A

  • Methods for detection of botulinum neurotoxin

    US20130065259A1

  • Antibodies to botulinum neurotoxins

    WO2023250381A2

Cited By

  • Antibody for long-acting neutralization of botulinum toxin A and application thereof

    CN119462913A